In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Pharmaceutical company GlaxoSmithKline Limited (GSK) in Kenya has officially changed its legal entity name to Haleon Kenya ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

But the shingles studies published in 2024, along with a host of new papers, add weight to an alternative decades-old ...

Apriori Bio has become the latest Flagship Pioneering-backed biotech to shed staff, cutting 15 workers to leave 21 still ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Vaccines Market Growth, Share Herpes simplex virus (HSV) is known for causing herpes infection. This is majorly ...

While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data ...

Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's ...